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Introduction
Hypertension is the most common chronic disease and 
about one billion people globally had hypertension in 2002.1 
It is the leading cause of death worldwide2 and the second 
leading cause of death in South Africa,3 most of these 
deaths resulting from complications of suboptimal blood 
pressure (BP) control. The prevalence of hypertension rises 
with age, and as many as 25% of South African adults were 
hypertensive in 2003.4,5
The current South African hypertension guideline6 is closely 
aligned to international hypertension guidelines and was 
developed to ensure, among other things, that BP is optimally 
controlled, appropriate lifestyle changes are reinforced and 
antihypertensive drugs are appropriately selected for the 
management of hypertension. Despite the effectiveness of 
antihypertensive drugs and lifestyle changes7 (weight loss, 
salt restriction, increased physical activity, limited alcohol 
intake and healthy diet) in lowering BP, these objectives are 
not being achieved,8,9 as shown by, e.g. a multi-facility survey 
in Cape Town, according to which BP control was achieved 
in only 33% of hypertensive patients.9 Poor adherence to 
guidelines, inappropriate choice of antihypertensives by 
clinicians and poor adherence to treatment by patients are 
partly responsible for this lamentable outcome.10
A sustained reduction of 5-6 mmHg in diastolic BP has 
been shown to reduce the incidence of stroke by nearly 
40%, coronary events by 15% and heart failure by 50%.5 
Hypertension management therefore requires effective 
control of BP to target in order for the burden and costs 
associated with cardiovascular (CV) diseases to be reduced, 
since the magnitude of BP reduction is a major determinant 
of the degree of reduction in CV risk.11 
The quality of care rendered to hypertensive patients can be 
assessed by determining, among other things, the extent 
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to which clinicians comply with clinical guidelines and the 
proportion of patients with controlled BP. 
Given the reported suboptimal management of hypertension 
in other South African settings and the lack of data in our 
local context, we conducted an audit to assess the extent 
to which BP was controlled to target, the appropriateness 
of antihypertensive therapy and the extent to which lifestyle 
modification was implemented among hypertensive 
patients in a large community health centre (CHC) south 
of Johannesburg. This article reports the audit findings, 
highlighting the clinical and public health implications for 
hypertension management and CV risk reduction.  
Method
Design and study setting
This audit involved a retrospective review of medical records 
and was conducted in the outpatient unit of a large CHC 
that forms part of a training complex for nurses, medical 
students and registrars in family medicine and primary 
health care (PHC). In this facility, three doctors and five 
PHC nurses provide care to a catchment population of 70 
000. While PHC nurses attend to less complicated patients, 
doctors attend to more complex cases, including those with 
uncontrolled hypertension. 
Criteria, standards and indicators
Quality health care is defined as desirable and achievable 
health care, and the main purpose of medical auditing is to 
make certain that the full benefits of medical knowledge are 
applied effectively to the needs of the patients.12 In order to 
assess the quality of care rendered, criteria and standards 
were set against which the performance of the system 
under scrutiny was compared. Criteria are measurable or 
definable items of health care that describe the quality of 
care and that can be used to assess it, while standards 
are the levels of care to be achieved for any particular 
criterion.13 Indicators are measurable variables related to 
the standard.14
The World Health Organization reports that only half (50%) of 
hypertensive patients on treatment have their BP controlled 
to target,15 and the Trialist collaboration found that less 
than 10% of the global population that could benefit from 
the lowering of BP are currently treated effectively.16 The 
authors of the current study therefore agreed on the criteria, 
indicators and standards shown in Table I.  
Samples and sampling method
An estimated 3 600 hypertensive patients are managed 
at the CHC targeted for the study. Assuming a margin of 
sampling error of 5%, a confidence level of 95% and a 
response distribution of 50%, a sample size of 300 patients 
was calculated to be adequate for this audit.17
In this CHC, hypertensive patients’ files are normally 
marked with a red sticker. After patients have consulted 
a clinician and collected their medications, all files are 
returned to the records registry where they are filed at the 
end of each working day. Consecutive files of hypertensive 
patients attended during the day were identified by the 
red sticker and selected for inclusion in the study at the 
end of every day. The number of files was cross-checked 
with the attendance register to ensure that all the files of 
hypertensive patients attended to were considered. Patients 
18 years and older were included. After the record review 
and extraction of information, patients’ files were marked to 
avoid repeated selection and returned to the registry daily. 
Selection continued until the required sample size was 
attained. 
Data collection and analysis
Information on patients’ details and process of care at the last 
clinic visit was extracted from patients’ files every day, onto 
an electronic data collection sheet. Information extracted 
included patients’ demographics (age, race, sex and level 
of education), anthropometric data (height, abdominal/
waist circumference and weight), clinical data (presence or 
absence of comorbid illnesses and BP recording during the 
last visit), data on antihypertensive therapy (types of drugs, 
dosages, combinations, duration and documentation of 
adherence to treatment and documentation of side-effects 
of medications) and clinical management data (follow-
up plans and documentation of lifestyle modification, as 
detailed in Table I).
Table I: Criteria, indicators and standards for the current audit6,15,16   
Criteria Indicators Standards
Control of BP to target 
range
BP readings:
General low-risk population <140/90 mmHg
Diabetic /heart failure ≤130/80 mmHg
Chronic renal disease ≤130/80 mmHg





Recognition of compelling indications for the use of class 
of drugs 
At least 80% of hypertensive patients are on appropriate 
choice of drug therapy.
Implementation of 
lifestyle modification
Documentation of advice on lifestyle changes (any of 
weight loss, increased physical activity, restricted salt 
intake, limited alcohol intake and healthy diet)
At least 80% of hypertensive patients are on lifestyle 
modification.
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Data was analysed using Epi-Info® version 3.5.1 (Centers 
for Disease Control and Prevention, Atlanta, Georgia, 
2008). Descriptive statistics was done with categorical data 
presented as percentages, proportions and frequencies, 
while continuous data were presented as means with their 
standard deviations. Comparisons between groups for 
categorical data were carried out using the chi-square test 
or Fisher’s exact test (where there were less than five data 
cells).18 For continuous data, the t-test was used. Results 
were considered statistically significant at P values less than 
0.05. Outcome measures were the proportion of patients 
with BP controlled to target, with appropriate choices of 
antihypertensive drug(s) and with documented lifestyle 
modifications. Results were compared with set standards 
derived from national and international hypertension 
guidelines (Table I) and inferences made from the system 
performance.
Ethics
Ethics approval was granted by the University of the 
Witwatersrand (certificate No. M10514) and permission 
was obtained from the Director of Sedibeng District Health 
Services. Patients’ files were coded and the names were 
not recorded.  
Results
Three hundred files were audited, of which 75.7% (n = 227) 
belonged to black and 24.3% (n = 73) belonged to white 
patients. The mean age was 60 years, with only 0.3% 
(n = 1) less than 30 years and 50% (n = 150) older than 
60 years. The mean duration of treatment was 5.6 years. 
Other patient characteristics are shown in Table II.
The mean systolic and diastolic BPs were 139.8 and 
83.2 mmHg respectively. BP control to target was achieved 
in 57% of patients. 
The classes of antihypertensive drugs prescribed for 
patients are shown in Table II. Angiotensin-converting 
enzyme (ACE) inhibitors were prescribed for almost equal 
proportions of black and white patients (72.7% vs. 72.1%). 
Calcium-channel blockers (CCBs) were prescribed for 
a greater proportion of black patients compared to white 
patients (62.6% vs. 31.5%). In contrast, β blockers (BBs) 
were prescribed for a greater proportion of white patients 
compared to black patients (8.2% vs. 3.1%).
Clinical comorbidity was documented in 21.3% 
(n = 64) of patients (Table II). Among patients with diabetes 
comorbidity, 83.3% (n = 10) had an ACE inhibitor prescribed. 
While diuretics were used in all patients with heart failure, 
furosemide was used in 63.9%, spironolactone in 11.1% 
and hydrochlorothiazide in 25%. Although 99.3% (n = 298) 
of patients had appropriate dosages of antihypertensive 
drugs prescribed, appropriate drug combinations was 
found in 81.3% (n = 244) of patients.   
Nearly all patients (99%, n = 297) had regular follow-up 
reviews, but lifestyle modification was documented in only 
56.3% (n = 169) of patients. 
Adherence to treatment was documented in 60% (n = 180) of 
patients. Of these patients, 57.2% (n = 103) were assessed 
to be adherent. Women were more likely to be adherent 
to treatment than men (P = 0.0028). Among other factors 
that influence BP control, white race and documented 
adherence to treatment were significantly associated with 
good BP control (P = 0.0001 and P = 0.0000 respectively). 
Male patients were significantly less likely to have their BP 
controlled compared to female patients (odds ratio 0.60, 
95% confidence interval: 0.37-0.98, P = 0.02; Table III). 
Table II: Patients’ demographic and clinical characteristics
Characteristics % (n) Mean ± SD
Age (years) 60 +/- 10.7
< 30 years 0.3 (1)
31-60 years 49.7 (149)













 Asthma 3.7 (11)
 Cardiac failure 12.0 (36)
 Diabetes mellitus 4.0 (12)
 Ischaemic heart disease 1.7 (5)
 None 78.7 (236)
BP at last clinic visit
 Systolic 139.8 mmHg  
± 18.7
 Diastolic 83.2 mmHg  
± 12.5
BP control to target
Controlled 57 (171)
Uncontrolled 43 (129)
Use of antihypertensive drugs
Diuretics 81 (243)  
ACE inhibitors 72.3 (217)
Calcium-channel blockers 55 (165)
β blockers 4.3 (13)
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Table III: Determinants of BP control




Combination of drugs 0.0668
Documentation of drug adherence 0.0000
Documentation of lifestyle modification 0.3845
BMI 0.3899
Follow-up scheduled 0.6082
System performance for BP control and appropriateness of 
drug therapy was acceptable (Table IV), but performance for 
implementation of lifestyle modification was poor and below 
set standards.
Table IV: Summary of major audit findings compared with set 
standards
Standards Major findings
At least 50% of hypertensive 
patients are controlled to target 
BP.
57% of hypertensive patients 
were controlled to target BP.
At least 80% of hypertensive 
patients are on appropriate 
choice of drug therapy.
81.3% of hypertensive patients 
were on appropriate choice of 
drug therapy.
At least 80% of hypertensive 
patients are on lifestyle 
modification.
56.3% of hypertensive patients 
were on lifestyle modification.
Discussion
This audit found that BP was controlled to target in the 
majority (57%) of patients, and as far as the authors are 
aware, most South African studies have reported BP 
control in between 24.5% and 44% of patients.8,9,19-21 
International reports including the United States National 
Health and Nutrition Examination Survey (2001–2002)22,23 
reported BP control in 53.1% of hypertensive patients, 
while an Irish survey24 found BP control in 48.6% of PHC 
patients. Achieving BP control in 57% of patients in a less 
resourced PHC setting suggests that PHC has the potential 
to play a pivotal role in the control of CV diseases in South 
Africa, since hypertension is the largest contributor to CV 
diseases.5 This achievement has the potential to translate 
into large-scale benefits at the population level, because a 
sustained reduction of 5-6 mmHg in diastolic BP reduces 
stroke by nearly 40%, coronary events by 15% and heart 
failure by 50%.5
In conformity with the literature,25 women in the current study 
were significantly more likely to have their BP controlled 
than men (P = 0.02; Table III). This is most likely explained 
by women’s better treatment adherence compared to men 
(P = 0.003) and the overall better utilisation of health care 
services compared to men.4,26 These behaviour patterns 
mean that women are more motivated to take responsibility 
for their health than men in South Africa. Health care 
providers need to be aware of this fact and invest more 
effort in motivating male patients to change their behaviour 
in an effort to improve their BP control. This is crucial in the 
management of hypertension, where a significant degree 
of patient involvement and self-motivation are needed for 
successful outcomes. 
Black patients have been reported to have a more severe 
form of hypertension and are less likely to achieve BP 
control.27 Belonging to the white race in this audit was 
significantly associated with good BP control compared to 
black patients (P = 0.0001). Poorer adherence to treatment, 
a general lower level of education and a weaker patient-
clinician engagement compared to white patients may 
account for this observation.28 These disparities have to be 
borne in mind during the management of black hypertensive 
patients, and efforts should be made to ensure that both 
patient education and BP control are intensified to limit 
complications.   
Weight loss, increased physical activity, salt restriction, 
limited alcohol intake and healthy diet, which are defined 
as lifestyle changes, have been shown to decrease BP.7,10,29 
However, only 56.3% of patients had lifestyle modification 
recorded despite 99% having had follow-up reviews. 
Opportunities provided by follow-up visits should be used to 
implement and reinforce lifestyle and behavioural changes, 
strategies that have been shown to lower BP.7 In this audit, 
55.7% of patients had a BMI greater than 25 kg/m2, way 
above the rate of 29.8% reported for being overweight in 
the 2003 South African Demographic and Health Survey.4 
Abdominal and waist circumferences were not documented, 
despite lifestyle modification being documented in 56.3% of 
patients. Obesity and increased abdominal circumference 
are common in South Africa30,31 and are strongly associated 
with hypertension and CV diseases. Since both obesity 
and increased abdominal circumference are amenable to 
lifestyle changes,7,31,32 health care providers should utilise 
the opportunity offered by follow-up reviews to engage 
their patients in weight loss and exercise. Where available, 
other team members such as clinical psychologists and 
health promoters should be utilised to encourage a healthy 
lifestyle among patients. 
The levels of education and socio-economic status of 
patients were not documented in this audit, and it was 
therefore not possible to explore the relationship between 
BP control and these latter two variables. Nonetheless, 
studies indicate that higher levels of education and socio-
economic status are significant predictors of better health 
outcomes, including BP control.25,26,33,34
Screening for comorbidity was rarely done, as this was 
documented in only 21.3% of patients. This omission 
has serious clinical implications since identification of 
comorbidity is an important task in risk stratification, which 
in turn is crucial for individualising the management of the 
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hypertensive patient. Such individualised management 
includes determining the BP threshold at which treatment 
is commenced, selecting the appropriate antihypertensive 
drug(s) for a particular patient and providing adjunct 
treatments that may be necessary for CV risk reduction 
in that patient.6,10 Active screening for complications 
and comorbidities should be the norm in PHC, as early 
interventions reverse or slow down the progression of 
complications.35 The absence of symptoms should not 
deter clinicians from screening for comorbidities because 
comorbidities are usually silent, as shown in a Cape Town 
study according to which 25% of men and 6% of women 
had silent renal disease.19 Setting up prompts may assist 
in reminding clinicians to screen for comorbidities and 
complications at intervals stipulated by guidelines.
The choice and combination of antihypertensive drugs 
were appropriate in 81.3% of patients while drug dosages 
were correct in 99.3% of patients. These results have 
important implications for BP control, especially in patients 
with comorbid illnesses. For example, all the patients 
with documented evidence of cardiac failure were started 
on diuretics. However, spironolactone was used less 
frequently despite evidence that it significantly improves 
outcomes in cardiac failure.36 In addition to their use in 
heart failure, diuretics, either alone or in combination with 
an ACE inhibitor, have been shown to reduce the incidence 
of stroke in several trials.37,38 In the current study, over 80% 
of all the patients with diabetes were started on an ACE 
inhibitor. CV risk associated with hypertension is amplified 
by diabetes,38 and early initiation of an ACE inhibitor and 
control of BP to less than 130/80 mmHg slow down the 
onset and progression of microvascular complications.39-43 
Thiazide diuretic was the most frequently used 
antihypertensive in line with recommendations that it be 
used as first-line drug treatment among black patients6,10 in 
whom hypertension has been linked to sodium metabolism 
abnormalities.8,32 However, the Baragwanath Hypertension 
Ambulatory Monitoring Study showed that a CCB in the 
form of nifedipine was superior to thiazide diuretics as 
monotherapy among black South Africans.44 In fact, a 
second agent was necessary for adequate BP control in 
most patients initially started on thiazide monotherapy. The 
clinical implication of this is that though sodium metabolism 
abnormalities are the overriding aberration among black 
patients, most will require a second antihypertensive drug 
in addition to an initial thiazide diuretic. 
ACE inhibitors were used more in white patients compared to 
blacks, rightly so because renin-angiotensin overactivity is 
the predominant underlying pathology in white hypertensive 
patients. The high efficacy of ACE inhibitors, especially 
when combined with diuretics, in preventing major CV 
events has also been shown by studies such as the HOPE45 
and ASCOT studies.46
Since the majority of the patients in this audit were 
black, it was not surprising that BBs were the least used 
antihypertensive. BBs are ineffective in the black South 
African population, and the increased risk of new onset 
type 2 diabetes, as shown in the ASCOT study,46 limits their 
use in this patient group, except where there are compelling 
indications against these limitations. 
Apart from female sex and white race, the documentation 
of adherence to treatment was the other factor found to 
be significantly associated with BP control (P = 0.000; 
Table III). This finding indicates that although the choice of 
antihypertensive drug is important in ensuring BP control, 
activities that improve patients’ understanding of their 
conditions and those that increase their participation in their 
own care are crucial for good outcomes. Patient education 
and adherence counselling should therefore be provided 
during clinic visits in PHC. Steps that promote adherence 
such as using a daily dose regimen, prescribing long-
acting agents, using drugs with a low side-effect profile 
and reducing the number of pills taken per day should be 
encouraged.5,25 While it is important to consider differences 
in class actions, it is detrimental to neglect treatment 
adherence, as the antihypertensive likely to provide clinical 
benefit is the one that the patient swallows consistently. 
This audit was a review of patients’ records and was 
therefore prone to information bias. Sampling consecutive 
patient files has the potential for selection bias, which 
may limit the generalisation of the findings to the entire 
hypertensive population in the CHC. The use of a single BP 
reading and not BP readings over time might have increased 
the risk of misclassifications of BP control. Despite these 
potential limitations, this audit provides an estimate of the 
quality of hypertension management at this CHC, and the 
findings provide bases for quality improvement processes 
and further studies on hypertension management in PHC.
In conclusion, BP control was achieved in the majority 
of patients and the choices of antihypertensives were 
appropriate in a vast majority. Regrettably, follow-up 
visits were not maximally utilised to promote lifestyle 
changes, which is clinically effective and doable within the 
consultation. Recognising the influence of race, sex and 
treatment adherence on the processes and outcomes of 
hypertension management is crucial in improving the care 
of hypertensive patients.
Improving the quality of medical records, conducting CV 
risk stratification, promoting lifestyle changes and providing 
adherence counselling during clinical encounters can 
improve hypertension management. Although drug therapy 
was appropriate in the majority of patients, ongoing training 
of PHC clinicians in evidence-based hypertension guidelines 
can sustain or improve on this high level of performance, 
ensuring that advancements in hypertension management 
are translated into clinical benefits for the individual patient.
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